GlassScriptPhysician profile
Michelle D Ovando
NPI 1760676969
$5,529.56
in general payments reported to CMS, 2019-2025
23 companies · $1,677 in 2025
The $1,677 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $980 · 2023: $1,270 · 2024: $1,418 · 2025: $1,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,204 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,203.68 |
| Education | $160.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,227.10 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $588.47 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $498.86 | 2021-2025 | |
| Lilly USA, LLC | $415.82 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $408.29 | 2022-2025 | Ilumya, Winlevi |
| Genzyme Corporation | $400.68 | 2023-2025 | |
| Pfizer INC. | $276.09 | 2022-2025 | |
| Janssen Biotech, INC. | $274.18 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Incyte Corporation | $223.82 | 2022-2025 | Opzelura |
| Ucb, INC. | $211.61 | 2022-2025 | Bimzelx |
| Amgen INC. | $195.88 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $151.39 | 2023-2025 | Nemluvio |
| Leo Pharma INC. | $134.61 | 2022-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $133.35 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $110.78 | 2023-2024 | Vtama |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $83.62 | 2022-2024 | Sotyktu |
| Fresenius Kabi USA, LLC | $60.49 | 2024 | Idacio |
| Biofrontera INC. | $31.83 | 2021-2024 | Ameluz, Rhodoled Xl, Xepi |
| Botanix Sb INC | $29.08 | 2025 | Sofdra |
| Epi Health, LLC | $22.17 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.40 | 2021 | |
| Organon LLC | $17.15 | 2024-2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.89 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Ovando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.